Patent ID: 6924100
Filing Date: 2005-08-02
Classification: A01K,A61K,A61P,C07K,C12N,C12Q,G01N

Abstract:
1. A method for evaluating responsiveness of an individual to treatment with an in vivo pharmaceutical wherein the in vivo pharmaceutical is one which activates G protein heterodimers containing a G protein subunit Gbeta3 or Gbeta3s comprising evaluating the individual for a genetic modification in a gene encoding a Gbeta3 subunit of a protein by detecting the genetic modification in the nucleic acid comprising SEQ ID NO: 2, wherein the genetic modification is a substitution of cytosine by thymidine at position 825 of SEQ ID NO:2, and wherein the thymidine at position 825 of SEQ ID NO: 2 is indicative of the individual having increased activation capacity of G proteins which is indicative of an altered responsiveness of the individual to the treatment with the in vivo pharmaceutical as compared to an individual having a cytosine at position 825 of SEQ ID NO:2.